The results indicate that the dual inhibition of EGFR and HER2 (human epidermal growth factor receptor 2) by afatinib, used for the treatment of non-small cell lung carcinoma (NSCLC), makes cells sensitive to radiation and reduces cell invasiveness. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.